Comparative Pharmacology
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus SECUADO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus SECUADO.
DAPIPRAZOLE HYDROCHLORIDE vs SECUADO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dapiprazole is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on the smooth muscle of the iris dilator muscle, causing miosis (pupil constriction).
SECUADO (asenapine) is an atypical antipsychotic with high affinity for serotonin 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors, as well as dopamine D2, D3, and D4 receptors. It also exhibits moderate affinity for histamine H1 and alpha2-adrenergic receptors, and low affinity for alpha1 and muscarinic receptors. The therapeutic effect in schizophrenia and bipolar disorder is primarily mediated through antagonism at D2 and 5-HT2A receptors.
5 mg orally once daily, titrated as needed up to 10 mg once daily.
Adults: 3.8 mg/24 hours applied transdermally once daily; initially 3.8 mg/24 hours, may titrate to 5.7 mg/24 hours, 7.6 mg/24 hours, or 11.4 mg/24 hours based on tolerability and efficacy. Maximum dose: 11.4 mg/24 hours.
None Documented
None Documented
Terminal elimination half-life is 78 hours; requires dose adjustment in renal impairment
Terminal elimination half-life: 20-24 hours; steady-state achieved within 5 days.
Primarily renal (80-90% as unchanged drug and metabolites); fecal (10-20%)
Primarily renal: 50-80% as unchanged drug; biliary/fecal: <15%.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic